Janux Therapeutics (NASDAQ:JANX) Insider Charles Winter Sells 2,401 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Charles Winter sold 2,401 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $32,965.73. Following the completion of the transaction, the insider directly owned 77,721 shares in the company, valued at $1,067,109.33. This trade represents a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Janux Therapeutics Price Performance

JANX opened at $13.65 on Friday. The business has a 50-day moving average of $22.51 and a 200-day moving average of $23.74. Janux Therapeutics, Inc. has a fifty-two week low of $13.52 and a fifty-two week high of $61.59. The company has a market capitalization of $821.05 million, a PE ratio of -8.13 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Janux Therapeutics

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Janux Therapeutics by 10.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after acquiring an additional 227,676 shares during the period. Orbimed Advisors LLC raised its stake in shares of Janux Therapeutics by 45.9% in the third quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company’s stock valued at $43,163,000 after buying an additional 555,800 shares during the period. Readystate Asset Management LP raised its holdings in Janux Therapeutics by 38.0% during the 3rd quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock valued at $23,472,000 after acquiring an additional 264,423 shares during the period. Geode Capital Management LLC lifted its stake in Janux Therapeutics by 15.5% during the second quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock worth $20,845,000 after purchasing an additional 121,403 shares during the last quarter. Finally, Prosight Management LP increased its holdings in shares of Janux Therapeutics by 1.3% in the third quarter. Prosight Management LP now owns 865,350 shares of the company’s stock worth $21,149,000 after buying an additional 11,446 shares during the period. Institutional investors own 75.39% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on JANX shares. Truist Financial began coverage on shares of Janux Therapeutics in a report on Wednesday, September 10th. They issued a “buy” rating and a $100.00 target price on the stock. Barclays decreased their price target on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 17th. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. Finally, UBS Group reaffirmed a “buy” rating and set a $57.00 price objective on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $61.08.

More Janux Therapeutics News

Here are the key news stories impacting Janux Therapeutics this week:

• Negative Sentiment: CEO David Alan Campbell sold 8,072 shares (~$110,829); he still holds 284,982 shares. Form 4 – Campbell
• Negative Sentiment: Insider Thomas Diraimondo sold 2,505 shares (~$34,394); remaining position ~124,425 shares. Form 4 – Diraimondo
• Negative Sentiment: Zachariah McIver sold 2,714 shares (~$37,263); post-sale holding ~23,286 shares. Form 4 – McIver
• Negative Sentiment: VP Maria Dobek sold 1,462 shares (~$20,073); holds ~15,373 shares after the sale. Form 4 – Dobek
• Negative Sentiment: Insider Charles M. Winter sold 2,401 shares (~$32,966); remaining holding ~77,721 shares. Form 4 – Winter

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.